Sanofi
Abstract digital art with flowing blue translucent waves on a blue-to-purple gradient background

Media Room

Two scientists wearing safety goggles and gloves, using a pipette to transfer a sample into an analysis plate.

Q3 2026 Results

Third quarter 2026 results were reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation was followed by a Q&A session.

Press Releases


November 18, 2026
Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease

October 30, 2026
Press Release: Q3 2026: double-digit growth in sales and business EPS FY 2026: guidance upgraded

October 20, 2026
Media Update: UEG Week: Sanofi and Teva’s duvakitug maintained long-term positive outcomes in new phase 2b data for ulcerative colitis and Crohn’s disease

Contact Our Media Team

You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.

Publications

July 2026

Half-year Financial Reports
Half Year 2026 Financial Report
Download
July 2026

Half-year Financial Reports
Half Year 2026 Financial Report (in French)
Download
July 2026

Half-year Financial Reports
Half Year 2026 Financial Report XBRL Package
Download .zip
October 2025

Annual Report on Form 20-F
Annual Report on Form 20-F 2025
Download